REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

19/02/2021 12:35

RNS Number : 7662P
  
GlaxoSmithKline PLC
  
19 February 2021
  
 

GlaxoSmithKline plc (the 'Company')
 
Transaction notification
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP & General Counsel




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
 
ISIN: US37733W1053




b)


Nature of the transaction


Following the vesting on 16 February 2021 of an award made on 6 September 2018 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Mr Ford will receive a cash payment of $225,308 less applicable tax withholding in respect of 6,320 notional American Depositary Shares.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


$35.6500


6,320


 




 


 


 


 




d)


Aggregated information


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2021-02-17




f)


Place of the transaction
 


N/A




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms D Waterhouse




b)


Position/status


CEO of ViiV Healthcare




c)


Initial notification/
amendment


Initial notification




2. 


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name 


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
 
ISIN: GB0009252882




b)


Nature of the transaction


Following the vesting on 16 February 2021 of an award made on 16 February 2015 under the GlaxoSmithKline Deferred Investment Award programme in lieu of a Share Value Plan award, Ms Waterhouse will receive a cash payment of £194,803.33 less applicable tax withholding in respect of 15,302.697 notional Ordinary Shares.




c)


Price(s) and volume(s)


 


Price(s)


Volume(s)


 




 


£12.7300
.


15,302.697


 




 


 


 


 




d)


Aggregated information


N/A (single transaction)




 
Aggregated volume Price


 




e)


Date of the transaction


2021-02-17




f)


Place of the transaction
 


N/A




 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
  END
 
 
DSHLKLFFFLLLBBK